Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies.

Trial Profile

Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cisplatin (Primary) ; Sodium metaarsenite (Primary)
  • Indications Cancer; Germ cell and embryonal neoplasms; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 01 Nov 2016 Status changed from recruiting to completed as per results published in the Cancer Chemotherapy and Pharmacology.
    • 01 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 21 Jul 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top